RS virus vaccine

Abstract

 RS virus infection is an important disease in infants and young children, but there is no effective prevention or treatment, and treatment is mainly conservative. Since 2000, the administration of the monoclonal antibody palivizumab has been used for high-risk infants. In 2024, a maternal-infant immune vaccine and the long-acting monoclonal antibody nirsevimab became available. In this paper, after describing the epidemiology of RS virus infection, we will outline the newly added vaccines and monoclonal antibodies, and consider prevention strategies for RS virus infection in Japan.